<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238537</url>
  </required_header>
  <id_info>
    <org_study_id>145671</org_study_id>
    <secondary_id>TGA Trial Number: 1999/271</secondary_id>
    <secondary_id>Enterprise ID: 15314</secondary_id>
    <nct_id>NCT00238537</nct_id>
  </id_info>
  <brief_title>Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)</brief_title>
  <official_title>Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET) in Acute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <brief_summary>
    <textblock>
      To determine whether the extent of the ischemic penumbra apparent on perfusion-diffusion MRI
      can be used to identify patients who would respond positively and safely to tissue
      plasminogen activator (tPA) beyond 3 hours post-stroke.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date>April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Hypothesis - lesion growth</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>In patients with penumbra, there will be attenuation of lesion growth (outcome T2 lesion volume - acute DWI volume ) with tPA.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Hypotheses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the non-penumbral group, lesion growth will be lower and will not be attenuated by tPA.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favourable functional outcome (mRS 0-2) will be more likely in patients with penumbra receiving tPA.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>That the proportion of patients achieving good neurological outcome (an 8 point improvement in NIH-SS or outcome NIH-SS of 0, 1) will be greater in those patients with a penumbra receiving tPA.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hemorrhagic transformation (sICH) will be predicted by the size of the baseline DWI volume in those patients receiving tPA.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reperfusion (greater than 90% PWI lesion reduction, or recanalisation on MRA, between the acute and sub-acute interval), will be increased (in patients with penumbra) receiving tPA.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with malignant mismatch (Definition DWI 100ml or more and / or PWI 100ml or more) there will be unfavourable clinical outcome (even if there is attenuation of growth).</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase t-PA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who present:

          -  with acute hemispheric stroke within 3-6 hours of onset,

          -  have at least moderate limb weakness,

          -  a National Institute of Health Stroke Scale (NIHSS) score &gt; 4,

          -  had a pre-stroke modified Rankin Scale (MRS) score of 0 - 2

          -  and who are able to undergo CT and MRI, are eligible for this study.

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding,

          -  persons who have CT-verified hemorrhagic stroke, major ischemia ( &gt; 33% of the middle
             cerebral artery (MCA) territory infarcted), subarachnoid hemorrhage, arteriovenous
             malformation, aneurysm, intracranial neoplasm that is terminal or poses a risk of
             hemorrhage ,

          -  are comatose or severely obtunded with fixed eye deviation and complete hemiplegia,

          -  have had another stroke within the past 6 weeks,

          -  have had a seizure prior to the administration of the study drug,

          -  have active peptic ulceration, bleeding diatheses, previous intracerebral hemorrhage,

          -  blood pressure &gt; 185/110,

          -  major surgery or trauma within the past 30 days, or any other contraindications to tPA

          -  have a presumed septic embolus or a myocardial infarction within the past 30 days

          -  blood glucose values are &lt; 2.8 or &gt; 22.0 mmol/L,

          -  pacemakers, aneurysm clips, implanted devices, claustrophobia, or any other
             contraindications to MRI,

          -  decreased consciousness,

          -  rapid clinical improvement,

          -  confounding neurological condition (e.g. dementia),

          -  any other life-threatening illness, or who are participating in another clinical
             trial, will be excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Davis, MD FRCP FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geoffrey Donnan, MD FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>National Stroke Research Institute, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter New England Area Health Service</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4072</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>92024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern General Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.astn.org.au/epithet/Epithet_home.htm</url>
    <description>Click here for more information about this study. Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>Stroke</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>MRI</keyword>
  <keyword>Echoplanar</keyword>
  <keyword>Penumbra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

